These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1250 related articles for article (PubMed ID: 35140113)

  • 21. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
    Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
    Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in
    Isomoto K; Haratani K; Hayashi H; Shimizu S; Tomida S; Niwa T; Yokoyama T; Fukuda Y; Chiba Y; Kato R; Tanizaki J; Tanaka K; Takeda M; Ogura T; Ishida T; Ito A; Nakagawa K
    Clin Cancer Res; 2020 Apr; 26(8):2037-2046. PubMed ID: 31937613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients.
    Huang P; Xu L; Jin M; Li L; Ke Y; Zhang M; Zhang K; Lu K; Huang G
    Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
    Sun H; Liu SY; Zhou JY; Xu JT; Zhang HK; Yan HH; Huan JJ; Dai PP; Xu CR; Su J; Guan YF; Yi X; Yu RS; Zhong WZ; Wu YL
    EBioMedicine; 2020 Oct; 60():102990. PubMed ID: 32927274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification and validation of tumor environment phenotypes in lung adenocarcinoma by integrative genome-scale analysis.
    Bi G; Chen Z; Yang X; Liang J; Hu Z; Bian Y; Sui Q; Li R; Zhan C; Fan H
    Cancer Immunol Immunother; 2020 Jul; 69(7):1293-1305. PubMed ID: 32189030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions.
    Chen K; Pan G; Cheng G; Zhang F; Xu Y; Huang Z; Fan Y
    Thorac Cancer; 2021 Jan; 12(2):218-226. PubMed ID: 33210451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive molecular analyses of cuproptosis-related genes with regard to prognosis, immune landscape, and response to immune checkpoint blockers in lung adenocarcinoma.
    Li R; Tong R; Zhang JL; Zhang Z; Deng M; Hou G
    J Cancer Res Clin Oncol; 2024 May; 150(5):246. PubMed ID: 38722401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of prognosis and immunotherapy efficacy based on metabolic landscape in lung adenocarcinoma by bulk, single-cell RNA sequencing and Mendelian randomization analyses.
    Liu Y; Zhang X; Pang Z; Wang Y; Zheng H; Wang G; Wang K; Du J
    Aging (Albany NY); 2024 May; 16(10):8772-8809. PubMed ID: 38771130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
    Liu SY; Dong ZY; Wu SP; Xie Z; Yan LX; Li YF; Yan HH; Su J; Yang JJ; Zhou Q; Zhong WZ; Tu HY; Yang XN; Zhang XC; Wu YL
    Lung Cancer; 2018 Nov; 125():86-92. PubMed ID: 30429043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
    Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
    Front Immunol; 2021; 12():723172. PubMed ID: 34539658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of JUN gene and cellular microenvironment in response to PD-1 blockade treatment in lung cancer patients via single-cell RNA sequencing.
    Wang Y; Ran T; Li Y; Tian L; Yang L; Liu Z; Yao B
    Aging (Albany NY); 2024 Jun; 16(12):10348-10365. PubMed ID: 38874497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer.
    Li LC; Chen XW; Fang L; Jian CL; Yu YX; Liao XY; Sun JG
    Can Respir J; 2023; 2023():4689004. PubMed ID: 37388902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multi-omics analysis of m
    Wu X; Bai Z
    Sci Rep; 2021 Oct; 11(1):20921. PubMed ID: 34686691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.
    Ishii H; Azuma K; Kawahara A; Kinoshita T; Matsuo N; Naito Y; Tokito T; Yamada K; Akiba J; Hoshino T
    Thorac Cancer; 2020 Apr; 11(4):950-955. PubMed ID: 32061060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tertiary Lymphoid Structure-Associated B Cells Enhance CXCL13
    Hu C; You W; Kong D; Huang Y; Lu J; Zhao M; Jin Y; Peng R; Hua D; Kuang DM; Chen Y
    Gastroenterology; 2024 Jun; 166(6):1069-1084. PubMed ID: 38445519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-cell dissection reveals the role of aggrephagy patterns in tumor microenvironment components aiding predicting prognosis and immunotherapy on lung adenocarcinoma.
    Sun X; Meng F; Nong M; Fang H; Lu C; Wang Y; Zhang P
    Aging (Albany NY); 2023 Dec; 15(23):14333-14371. PubMed ID: 38095634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of PRDX4 and the EGFR mutation status on cellular proliferation in lung adenocarcinoma.
    Mizutani K; Guo X; Shioya A; Zhang J; Zheng J; Kurose N; Ishibashi H; Motono N; Uramoto H; Yamada S
    Int J Med Sci; 2019; 16(9):1199-1206. PubMed ID: 31588184
    [No Abstract]   [Full Text] [Related]  

  • 40. Comparative profiling of single-cell transcriptome reveals heterogeneity of tumor microenvironment between solid and acinar lung adenocarcinoma.
    Li D; Yu H; Hu J; Li S; Yan Y; Li S; Sun L; Jiang G; Hou L; Zhang L; Zhang P
    J Transl Med; 2022 Sep; 20(1):423. PubMed ID: 36138435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 63.